Syndax Revuforj Sales Climb 90% To $60.7 Million As Leukemia Drugmaker Swaps CFOs

Third-quarter revenue rose 82% to $83.3 million, the net loss narrowed, and Aaron Ondrey replaces retiring CFO Keith Goldan on November 9.

Share
Syndax Revuforj Sales Climb 90% To $60.7 Million As Leukemia Drugmaker Swaps CFOs

Syndax Pharmaceuticals, a commercial-stage company that develops cancer therapies, reported third-quarter revenue of $83.3 million, up 82% from a year earlier, in an 8-K filed Monday. The company also said CFO Keith Goldan will retire and Aaron Ondrey will take over.

Two drugs, $83.3 million

Revuforj, the oral leukemia drug, brought in $60.7 million of net revenue, up 90% from the third quarter of 2025 and 11% from the second quarter. New patients rose about 20% and total prescriptions about 13% from the prior quarter.

The other $22.6 million was collaboration revenue from Niktimvo, which Syndax co-commercializes with Incyte. That is Syndax's 50% share of Niktimvo's net commercial profit, which is net revenue minus cost of sales and commercial expenses. Incyte reported Niktimvo net revenue of $67.4 million, up 47% from a year earlier.

CEO Michael Metzger said a growing number of relapsed or refractory patients are proceeding to a stem cell transplant after Revuforj and then resuming therapy. Claims data indicate about 50% of KMT2A-rearranged patients get a transplant, and about 60% of them resume therapy afterward.

A narrower loss, rising research bill

The net loss attributable to common stockholders narrowed to $49.4 million, or $0.55 per share, from $60.7 million, or $0.70 per share, a year earlier. Research spending rose to $67.5 million from $56.3 million, which the company attributed mainly to frontline trials of revumenib, Revuforj's active ingredient, in newly diagnosed acute myeloid leukemia. Selling, general and administrative costs fell to $43.7 million from $44.9 million.

Syndax held $551.1 million in cash and investments at September 30 and still expects 2026 research plus selling and administrative expenses of about $400 million, excluding $50 million of estimated non-cash stock compensation.

In October, the company said a mid-stage trial of Niktimvo in idiopathic pulmonary fibrosis missed its main goal, and it does not plan further development in that disease.

Ondrey steps in November 9

Goldan retires as CFO effective November 9 and will then serve as an advisor for an interim period. Ondrey joins that day; he was most recently CFO of Beren Therapeutics, a private company, and earlier held the CFO job at Rocket Pharmaceuticals and Mirati Therapeutics.

His contract sets a $543,000 base salary, a target bonus of 45% of salary and an option on 270,000 shares priced at the November 9 close.

Syndax expects new Revuforj frontline, post-transplant and real-world data in the fourth quarter.

Syndax said it will present those fourth-quarter data at upcoming medical meetings, including ASH.

Sources

More on Syndax Pharmaceuticals

All Syndax Pharmaceuticals (SNDX) coverage →